Cleveland BioLabs, Inc. CBLI announced today that it has received a Notice of Allowance from the Japan Patent Office for a CBLB502 patent application. Allowed claims cover the method of protecting a mammal from radiation using flagellin or its derivatives, including CBLB502.
Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, stated, "This Notice of Allowance expands validation of our claims regarding protection from radiation with CBLB502 and other flagellin derivatives in major jurisdictions worldwide including the United States, Europe, Eurasia, China, and now Japan. We remain focused on advancing CBLB502 towards a biologic license application with the FDA."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in